Literature DB >> 16624549

International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age.

Hideki Sano1, Jeffrey Bonadio, Robert B Gerbing, Wendy B London, Katherine K Matthay, John N Lukens, Hiroyuki Shimada.   

Abstract

Age has been used as a prognostic factor for patients with peripheral neuroblastic tumours (pNTs). The latest analysis disclosed a cut-off around 18 months for the optimal prognostic distinction. The International Neuroblastoma Pathology Classification (INPC) distinguishes favourable and unfavourable histology based on the age-appropriate evaluation of histologic indicators (grade of neuroblastic differentiation, mitosis-karyorrhexis index) in the categories of neuroblastoma and ganglioneuroblastoma, nodular. This study showed that age tested by using 3 different cut-offs (12, 18, 24 months) was prognostically significant. INPC remained prognostically significant regardless of the age group to which it was applied. Prognostic effects of age and histologic indicators were independently significant, i.e., age had prognostic ability beyond that of histologic indicators, and histologic indicators had prognostic ability beyond that of age. Due to the fact that INPC incorporated age factor (18, 60 months) in the system, it served better than age by itself for prognostic distinction of pNT patients.

Entities:  

Mesh:

Year:  2006        PMID: 16624549     DOI: 10.1016/j.ejca.2005.11.031

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Primitive neuroectodermal peripheral tumour of the retroperitoneum.

Authors:  C Alvarez-Laso; E Azcano; J González; I González-Pinto
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

2.  Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma.

Authors:  Tomoro Hishiki; Hiroshi Horie; Yasuyuki Higashimoto; Katsumi Yotsumoto; Shugo Komatsu; Yuri Okimoto; Harumi Kakuda; Yuichi Taneyama; Takeshi Saito; Keita Terui; Tetsuya Mitsunaga; Mitsuyuki Nakata; Hidemasa Ochiai; Moeko Hino; Kumiko Ando; Hideo Yoshida; Jun Iwai
Journal:  Pediatr Surg Int       Date:  2014-07-27       Impact factor: 1.827

3.  Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.

Authors:  Setsuko Kaneko; Miki Ohira; Yohko Nakamura; Eriko Isogai; Akira Nakagawara; Michio Kaneko
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-07       Impact factor: 4.553

4.  Phox2B correlates with MYCN and is a prognostic marker for neuroblastoma development.

Authors:  Xiao-Xue Ke; Dunke Zhang; Hailong Zhao; Renjian Hu; Zhen Dong; Rui Yang; Shunqin Zhu; Qingyou Xia; Han-Fei Ding; Hongjuan Cui
Journal:  Oncol Lett       Date:  2015-03-31       Impact factor: 2.967

5.  Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.

Authors:  Elizabeth Sokol; Ami V Desai; Mark A Applebaum; Dominique Valteau-Couanet; Julie R Park; Andrew D J Pearson; Gudrun Schleiermacher; Meredith S Irwin; Michael Hogarty; Arlene Naranjo; Samuel Volchenboum; Susan L Cohn; Wendy B London
Journal:  J Clin Oncol       Date:  2020-04-21       Impact factor: 44.544

6.  Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.

Authors:  Roberta Vitali; Camillo Mancini; Vincenzo Cesi; Barbara Tanno; Marta Piscitelli; Mariateresa Mancuso; Fabiola Sesti; Emanuela Pasquali; Bruno Calabretta; Carlo Dominici; Giuseppe Raschellà
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

Review 7.  Neuroblastoma: biology and staging.

Authors:  Sabine Mueller; Katherine K Matthay
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

Review 8.  Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

Authors:  Wendy B London; Rochelle Bagatell; Brenda J Weigel; Elizabeth Fox; Dongjing Guo; Collin Van Ryn; Arlene Naranjo; Julie R Park
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

9.  Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

Authors:  Daniel A Morgenstern; Wendy B London; Derek Stephens; Samuel L Volchenboum; Barbara Hero; Andrea Di Cataldo; Akira Nakagawara; Hiroyuki Shimada; Peter F Ambros; Katherine K Matthay; Susan L Cohn; Andrew D J Pearson; Meredith S Irwin
Journal:  J Clin Oncol       Date:  2014-03-24       Impact factor: 44.544

10.  S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.

Authors:  Wei Wu; Shao Jingbo; Weijue Xu; Jiangbin Liu; Yiming Huang; Qingfeng Sheng; Zhibao Lv
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.